Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.63 [0.48, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | crucial | - |
deaths (OS) (extension) | 0.63 [0.52, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
PFS (extension) | 0.53 [0.44, 0.64] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.57 [0.43, 0.76] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 3.40 [2.02, 5.72] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
objective responses (ORR) (extension) | 3.54 [2.46, 5.10] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
TRAE (any grade) | 1.01 [0.64, 1.59] | | < 1 | | 0% | 1 study (1/-) | 48.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.71 [0.49, 1.03] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.72 [0.45, 1.13] | | < 1 | | 0% | 1 study (1/-) | 92.2 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 0.52 [0.31, 0.88] | | < 1 | | 0% | 1 study (1/-) | 99.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.25 [0.01, 5.50] | | < 1 | | 0% | 1 study (1/-) | 80.8 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 1.99 [0.18, 22.10] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.50 [0.04, 5.49] | | < 1 | | 0% | 1 study (1/-) | 71.5 % | NA | not evaluable | | non important | - |
Colitis TRAE (grade 3-4) | 0.12 [0.03, 0.39] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Cough TRAE (grade 3-4) | 3.99 [0.18, 88.92] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.48 [0.21, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.0 % | NA | not evaluable | | non important | - |
Dry skin TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Dyspnoea TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.99 [0.20, 4.96] | | < 1 | | 0% | 1 study (1/-) | 50.3 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.20 [0.02, 1.69] | | < 1 | | 0% | 1 study (1/-) | 93.0 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 1.50 [0.25, 9.01] | | < 1 | | 0% | 1 study (1/-) | 33.1 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.79 [0.21, 2.98] | | < 1 | | 0% | 1 study (1/-) | 63.5 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 1.17 [0.53, 2.56] | | < 1 | | 0% | 1 study (1/-) | 35.1 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 1.99 [0.18, 22.10] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
Myalgia TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.25 [0.01, 5.50] | | < 1 | | 0% | 1 study (1/-) | 80.8 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
Pruritic rash TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.20 [0.02, 1.69] | | < 1 | | 0% | 1 study (1/-) | 93.0 % | NA | not evaluable | | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.99 [0.02, 50.24] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
Vitiligo TRAE (grade 3-4) | 1.99 [0.07, 59.55] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.99 [0.06, 15.96] | | < 1 | | 0% | 1 study (1/-) | 50.2 % | NA | not evaluable | | non important | - |
Weight decreased TRAE (grade 3-4) | 0.50 [0.02, 14.84] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |